Get started
AMICOGEN, INC.AA

AMICOGEN, INC.

3,815KRWD
−185−4.63%
At close at 07:20 GMT
KRW
No trades
See on Supercharts
Overview
Financials
Discussions Technicals Seasonals

092040 fundamentals

Key facts

Market capitalization‪219.26 B‬KRW
Dividend yield (indicated)—
Price to earnings Ratio (TTM)—
Basic EPS (TTM)−966.13KRW
Founded2000
Employees (FY)223
CEOCheol Park
Websiteamicogen.com
About

Amicogen, Inc. engages in the development and sale of enzyme products and functional food materials. Its products include specialty enzyme for pharmaceutical, food, feed, and industrial; new bio-ingredients such as natural health ingredients for food, feed and cosmetics; and immunological products such as protein A resin. The company was founded on May 29, 2000 and is headquartered in Jinju-si, South Korea.

Ownership
‪‪54.82 M‬‬
Free Float shares
‪‪44.29 M‬‬ (80.8%)
Closely held shares
‪‪10.52 M‬‬ (19.2%)
Free Float shares
‪‪44.29 M‬‬ (80.8%)
Closely held shares
‪‪10.52 M‬‬ (19.2%)
Capital structure
Market cap
‪‪219.26 B‬‬
Debt
‪‪120.09 B‬‬
Minority interest
‪‪604.21 M‬‬
Cash & equivalents
‪‪17.72 B‬‬
Enterprise value
‪‪322.24 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪219.26 B‬‬
Price to earning ratio (P/E)
—
Price to sales ratio (P/S)
1.46x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
—
Price to sales ratio (P/S)
1.46x
Valuation ratios
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪0.80‬
‪1.60‬
‪2.40‬
‪3.20‬
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−75%‬
‪−50%‬
‪−25%‬
‪0%‬
‪25%‬
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪‪−60.00 B‬‬
‪‪−30.00 B‬‬
‪0.00‬
‪‪30.00 B‬‬
‪‪60.00 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−12.00 B‬‬
‪‪−6.00 B‬‬
‪0.00‬
‪‪6.00 B‬‬
‪‪12.00 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−12.00 B‬‬
‪‪−6.00 B‬‬
‪0.00‬
‪‪6.00 B‬‬
‪‪12.00 B‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Raw Pharmaceutical Products
Special Enzymes, Bio-new Materials, Bio-medical Materials, Health and Beauty
By country
Period: 2024
Overseas
South Korea

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
2020
2021
2022
2023
‪0.00‬
‪‪200.00 B‬‬
‪‪400.00 B‬‬
‪‪600.00 B‬‬
‪‪800.00 B‬‬
Estimate
Earnings
Next:—
2020
2021
2022
2023
‪0.00‬
‪130.00‬
‪260.00‬
‪390.00‬
‪520.00‬
Estimate

Dividends

Dividend yield, history and sustainability

No dividends
092040 has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company

Debt level and coverage
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪‪−60.00 B‬‬
‪0.00‬
‪‪60.00 B‬‬
‪‪120.00 B‬‬
‪‪180.00 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪60.00 B‬‬
‪‪120.00 B‬‬
‪‪180.00 B‬‬
‪‪240.00 B‬‬
Assets
Liabilities